Bank of New York Mellon Corp Increases Stake in Pernix Therapeutics Holdings, Inc. (PTX)
Bank of New York Mellon Corp raised its stake in Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) by 27.8% during the first quarter, Holdings Channel reports. The fund owned 31,710 shares of the specialty pharmaceutical company’s stock after buying an additional 6,907 shares during the period. Bank of New York Mellon Corp’s holdings in Pernix Therapeutics Holdings were worth $118,000 at the end of the most recent reporting period.
Pernix Therapeutics Holdings, Inc. (NASDAQ PTX) traded down 7.84% during midday trading on Friday, reaching $2.47. 304,343 shares of the company traded hands. The stock’s market capitalization is $27.46 million. The company has a 50 day moving average price of $3.69 and a 200-day moving average price of $3.81. Pernix Therapeutics Holdings, Inc. has a one year low of $0.40 and a one year high of $7.15.
Pernix Therapeutics Holdings (NASDAQ:PTX) last posted its quarterly earnings results on Thursday, July 27th. The specialty pharmaceutical company reported ($2.16) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($4.40) by $2.24. The company had revenue of $34.32 million during the quarter. Analysts forecast that Pernix Therapeutics Holdings, Inc. will post ($3.70) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This report was reported by Daily Political and is the sole property of of Daily Political. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.dailypolitical.com/2017/08/12/bank-of-new-york-mellon-corp-increases-stake-in-pernix-therapeutics-holdings-inc-ptx.html.
Separately, ValuEngine lowered shares of Pernix Therapeutics Holdings from a “sell” rating to a “strong sell” rating in a research note on Saturday, July 8th.
About Pernix Therapeutics Holdings
Pernix Therapeutics Holdings, Inc is a specialty pharmaceutical company. The Company focuses on identifying, developing and commercializing differentiated products that address unmet medical needs. It focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas.
Want to see what other hedge funds are holding PTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX).
Receive News & Ratings for Pernix Therapeutics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pernix Therapeutics Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.